AASLD guidelines for the treatment of hepatocellular carcinoma

By J. Heimbach, L. Kulik, R. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. H. Murad, Jorge Marrero. Hepatology, 2018

3,751 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/17a6ac1725ca0a3e1502230fa54842f06cbc155f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. J. Lavine
7. N. Chalasani
8. S. Harrison

In Hepatology

1. Z. Younossi
2. M. Rinella
3. J. Llovet
4. V. Mazzaferro
5. Amit G. Singal
6. Alejandro Forner1 , 2
7. Andrew X. Zhu
8. Peter R. Galle

Citations in the corpus

• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, methodology): “Based on a recent systematic review of the available evidence, the current AASLD Guideline recommends surveillance for individuals with cirrhosis as shown in Table 1.(2) The modalities recommended for surveillance are liver US with or without AFP every 6 months.”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, methodology): “Patients with cirrhosis suspected due to NAFLD should be considered for HCC screening according to the AASLD practice guidelines (263).”
• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, methodology): “Based on a recent systematic review of the available evidence, the current AASLD Guideline recommends surveillance for individuals with cirrhosis as shown in Table 1.(2) The modalities recommended for surveillance are liver US with or without AFP every 6 months.”
• Advances in immunotherapy for hepatocellular carcinoma (2021, neutral): “Atezolizumab (1,200 mg every 3 weeks) No 1L 59 42 66 32 17 (5) 42 NA 131”
• Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, methodology): “The AASLD 2018 Practice Guidelines on HCC has been published.((133)) Of the 2 tests prospectively evaluated as screening tools for HCC, alphafetoprotein (AFP) and ultrasonography (US), the sensitivity, specificity, and diagnostic accuracy of US are higher than those of AFP.”
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “are considered eligible for LT, while those beyond Milan can be offered LT only after successful downstaging into Milan criteria.(401)”
• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[135,140] Therefore, patients with non-characteristic imaging are advised to undergo biopsy, independent of AFP level.”
• Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis (2018, methodology): “without AFP, as it is “not possible to determine which type of surveillance test, US alone or the combination of US plus AFP, leads to greater improvement in survival”.(10) This recommendation represents a departure from prior AASLD guidelines and current EASL guidelines, which recommend against use”